Skip to main content

Publications

This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

149 result(s)

phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2 

Navarro-Compán Victoria, Ramiro Sofia, Deodhar Atul et al.  April 10, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

Lebwohl Mark, Joseph F Merola, Strober Bruce et al.  April 06, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab-bkzx Journal Scan: 4 Clinical Trials

Jason Hawkes et al.  March 25, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials

Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  March 15, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison 

Richard B Warren, Iain B McInnes, Nash Peter et al.  March 15, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison 

Philip J Mease, Richard B Warren, Nash Peter et al.  March 06, 2024
phase 4

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis

Jerzy P Szaflarski, Hervé Besson, Wendyl D'Souza et al.  March 04, 2024
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
phase 3

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia Gravis
View

Improvement of fatigue in generalised myasthenia gravis with zilucoplan

Weiss D. Michael, Freimer Miriam, M. Isabel Leite et al.  February 24, 2024